Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr. Hector, Barajas-Martinez

Dr. Hector, Barajas-Martinez

CEO
Global Genetics Corporation and Scientific Chief Officer (SCO) of CAMDIA MEDICAL LLC
USA

Biography

Dr. Hector, Barajas-Martinez (PhD in Human Genetics and Fellow of Heart Rhythm Society) is currently the CEO of Global Genetics Corporation and Scientific Chief Officer (SCO) of CAMDIA MEDICAL LLC in Ventura, California. He is a new Special Section Editor of Electrocardiology and Genetics/Inherited Arrhythmia Disorders below to peer review Journal of Electrocardiology. He was a Clinical Director of Molecular Genetics/ Research Scientist at Molecular Genetics & Experimental Cardiology, Masonic Medical Research Laboratory in Utica, New York USA. Over the last 20 years or more he has been fully committed to advancing translational research in the field of genetics in cardiac arrhythmias. His new role in the Molecular Genetics and Functional Genomics Programs is to establish new strategies for molecular genetic approaches to identified new genetic markers in Inherited Cardiac Death Syndromes, Neuronal and Cancer diseases. He played a key role in the discovery and characterization of more than 8 new genes related to Brugada, Early Repolarization, Short and Long QT Syndromes and Hypertrophic and Dilated Cardiomyopathies, which were published in top tier scientific journals. We are interested in helping to identify novel gene or multiple genes mutations linked to inherited cardiac, diabetes, obesity, cancer and neuropathology syndromes associated with ion channels and structural gene-diseases.

Research Interest

One of the principal goals is looking for new genomic medicine discoveries to decrease mortality in sudden cardiac arrhythmias in children and adults. R&D and educational training is highly important to advance our understanding of their genetic and epigenetic role in the genotype-phenotype correlation at the molecular and functional levels for potential therapies.